Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
Oragenics (NYSE: OGEN) has announced a 1-for-30 reverse stock split of its common stock, effective June 3, 2025. Following the split, every 30 pre-split shares will automatically combine into one new share, with fractional shares rounded up to the nearest whole share. The reverse split was approved by the Board on May 27, 2025, after receiving shareholder authorization for a split ratio between 1-for-5 and 1-for-50.
The company's stock will continue trading under the symbol "OGEN" with a new CUSIP number (684023 609). The split will not affect the par value of common stock or authorized but unissued shares. CEO Janet Huffman stated that this move aims to strengthen their capital markets presence and attract long-term, quality-focused investors.
Oragenics (NYSE: OGEN) ha annunciato un split azionario inverso 1-per-30 delle sue azioni ordinarie, che entrerà in vigore il 3 giugno 2025. Dopo lo split, ogni 30 azioni precedenti verranno automaticamente raggruppate in una nuova azione, con le frazioni di azioni arrotondate per eccesso all'azione intera più vicina. Lo split inverso è stato approvato dal Consiglio di Amministrazione il 27 maggio 2025, dopo aver ottenuto l'autorizzazione degli azionisti per un rapporto di split compreso tra 1-per-5 e 1-per-50.
Le azioni della società continueranno a essere negoziate con il simbolo "OGEN" e un nuovo numero CUSIP (684023 609). Lo split non influenzerà il valore nominale delle azioni ordinarie né le azioni autorizzate ma non emesse. La CEO Janet Huffman ha dichiarato che questa operazione mira a rafforzare la presenza nei mercati finanziari e ad attrarre investitori di qualità con un orientamento a lungo termine.
Oragenics (NYSE: OGEN) ha anunciado una consolidación inversa de acciones 1 por 30 de sus acciones ordinarias, que entrará en vigor el 3 de junio de 2025. Tras la consolidación, cada 30 acciones anteriores se combinarán automáticamente en una nueva acción, redondeando las fracciones hacia arriba al número entero más cercano. La consolidación inversa fue aprobada por la Junta Directiva el 27 de mayo de 2025, luego de recibir autorización de los accionistas para una proporción de consolidación entre 1 por 5 y 1 por 50.
Las acciones de la compañía seguirán cotizando bajo el símbolo "OGEN" con un nuevo número CUSIP (684023 609). La consolidación no afectará el valor nominal de las acciones ordinarias ni las acciones autorizadas pero no emitidas. La CEO Janet Huffman declaró que esta medida busca fortalecer su presencia en los mercados de capital y atraer inversores de calidad con visión a largo plazo.
Oragenics (NYSE: OGEN)는 2025년 6월 3일부터 효력이 발생하는 1대 30 역주식 병합을 발표했습니다. 병합 후 기존 주식 30주가 자동으로 1주로 합쳐지며, 소수 주식은 가장 가까운 정수로 반올림됩니다. 이 역병합은 2025년 5월 27일 이사회에서 승인되었으며, 주주로부터 1대 5에서 1대 50 사이의 병합 비율에 대한 승인을 받았습니다.
회사의 주식은 "OGEN"이라는 심볼로 계속 거래되며, 새로운 CUSIP 번호(684023 609)가 부여됩니다. 이번 병합은 보통주의 액면가나 승인되었으나 발행되지 않은 주식 수에는 영향을 미치지 않습니다. CEO Janet Huffman은 이번 조치가 자본 시장에서의 입지를 강화하고 장기적이고 질 높은 투자자를 유치하는 데 목적이 있다고 밝혔습니다.
Oragenics (NYSE : OGEN) a annoncé un regroupement d’actions inverse au ratio de 1 pour 30 de ses actions ordinaires, effectif à partir du 3 juin 2025. Après le regroupement, chaque tranche de 30 actions précédentes sera automatiquement convertie en une nouvelle action, les fractions d’actions étant arrondies à l’action entière la plus proche. Ce regroupement a été approuvé par le conseil d’administration le 27 mai 2025, après avoir obtenu l’autorisation des actionnaires pour un ratio de regroupement compris entre 1 pour 5 et 1 pour 50.
Les actions de la société continueront d’être négociées sous le symbole « OGEN » avec un nouveau numéro CUSIP (684023 609). Ce regroupement n’affectera pas la valeur nominale des actions ordinaires ni le nombre d’actions autorisées mais non émises. La PDG Janet Huffman a déclaré que cette opération vise à renforcer leur présence sur les marchés financiers et à attirer des investisseurs de qualité, axés sur le long terme.
Oragenics (NYSE: OGEN) hat eine 1-zu-30 Reverse-Aktienzusammenlegung seiner Stammaktien angekündigt, die am 3. Juni 2025 wirksam wird. Nach der Zusammenlegung werden jeweils 30 Altaktien automatisch zu einer neuen Aktie zusammengefasst, wobei Bruchstücke auf die nächsthöhere ganze Aktie aufgerundet werden. Die Reverse-Split wurde vom Vorstand am 27. Mai 2025 genehmigt, nachdem die Aktionäre eine Ermächtigung für ein Split-Verhältnis zwischen 1-zu-5 und 1-zu-50 erteilt hatten.
Die Aktien des Unternehmens werden weiterhin unter dem Symbol „OGEN“ gehandelt und erhalten eine neue CUSIP-Nummer (684023 609). Die Zusammenlegung wirkt sich nicht auf den Nennwert der Stammaktien oder die genehmigten, aber noch nicht ausgegebenen Aktien aus. CEO Janet Huffman erklärte, dass dieser Schritt darauf abzielt, die Präsenz auf den Kapitalmärkten zu stärken und langfristig orientierte Qualitätsinvestoren anzuziehen.
- Potential to meet minimum share price requirements for continued NYSE American listing
- May attract more institutional investors due to higher share price
- Could improve stock marketability and trading profile
- Significant reduction in the number of outstanding shares could impact liquidity
- No fundamental change in company value or market capitalization
- Historical tendency for reverse splits to be viewed negatively by the market
Insights
Oragenics' 1-for-30 reverse split aims to boost share price but signals concerning financial position requiring drastic action.
Oragenics has announced a substantial 1-for-30 reverse stock split effective June 3, 2025, a significant corporate action that will dramatically reduce their outstanding share count while proportionally increasing the share price. This is an aggressive consolidation ratio that exceeds typical reverse splits (usually in the 1-for-5 to 1-for-20 range).
The primary motivation behind this drastic measure appears to be maintaining NYSE American listing compliance, which requires minimum share prices. While CEO Janet Huffman frames this as "strengthening capital markets presence" and attracting "quality-focused investors," reverse splits of this magnitude typically indicate serious underlying financial challenges rather than strength.
Historical market data shows reverse splits are often received negatively by investors, as they're frequently employed by companies struggling with severely depressed share prices. The split changes nothing fundamental about Oragenics' enterprise value or financial health - it's purely a mathematical adjustment that reduces share count while proportionally increasing price.
This action follows shareholder approval for a split ratio between 1-for-5 and 1-for-50, with management choosing a ratio near the higher end of that range, suggesting significant price deterioration. Notably, the company chose to round fractional shares up rather than cash them out, which benefits small shareholders but slightly dilutes larger holders.
While this maneuver buys Oragenics time to execute its biotech strategy focused on "brain-related health conditions," investors should recognize this as a warning sign rather than a catalyst, potentially indicating capital raising challenges in the near future.
SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the “Board”) on May 27, 2025 approved a One-for-Thirty (1-for-30) reverse stock split of the Company’s issued and outstanding shares of common stock, par value
As a result of the Reverse Stock Split, every 30 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of holders. Any fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per shareholder basis. Proportionate adjustments will be made to (i) shares of common stock issuable upon exercise or conversion of all issued and outstanding options, warrants and convertible securities of every kind, and (ii) shares outstanding and authorized for issuance under the Company’s 2021 Equity Incentive Plan, as amended. The Reverse Stock Split will not affect the par value of the common stock, nor the number of authorized but unissued shares of common stock, nor the Company’s authorized preferred stock, except, with regard to the preferred stock, to affect, where applicable, the conversion rates of outstanding shares of preferred stock.
The Board approved the Reverse Stock Split ratio after the Company’s shareholder approved providing the Board with authority to enact a reverse stock split in a ratio between one-for-five and one-for-fifty. The Company anticipates that the effective time of the Reverse Stock Split will be 12:01 a.m. Eastern Time on June 3, 2025, with the common stock trading on a post-split basis when the market opens on June 3, 2025 under the existing trading symbol “OGEN” with a new CUSIP number, 684023 609. The Reverse Stock Split will increase the market price per share of the Company’s common stock.
Commenting on the matter, Chief Executive Officer, Ms. Janet Huffman, stated: “The reverse split reinforces our commitment to strengthening our capital markets presence. By increasing our share price and reducing share count, we believe we’ll be better aligned with the expectations of long-term, quality-focused investors who share our vision for transforming neurological care.”
The Company’s transfer agent, Continental Stock Transfer & Trust, will provide instructions to shareholders regarding the process for exchanging shares. Continental Stock Transfer & Trust can be reached by phone at (917) 262-2378 or mail at 1 State Street, 30th Floor, New York, NY 10004-1561.
About Oragenics, Inc.
Oragenics is a clinical-stage biotechnology company focused on developing breakthrough treatments for neurological disorders. The company’s lead asset, ONP-002, is an innovative intranasal therapy designed to address the unmet medical need in concussion treatment. Oragenics is committed to pioneering new approaches in neuroscience to improve patient outcomes. For more information, visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.
Investor Contact
Rich Cockrell
404.736.3838
ogen@cg.capital
FAQ
When will OGEN's 1-for-30 reverse stock split take effect?
What happens to fractional shares in OGEN's reverse stock split?
Will OGEN's stock symbol change after the reverse split?
How will OGEN's reverse split affect existing shareholders?
What is the purpose of OGEN's reverse stock split?
